IRB and other research regulatory professionals in the United States may not be familiar with Tecovirimat (TPOXX). This explainer is intended to acquaint them with basic facts about TPOXX and the efforts currently underway to 1) use it to treat patients with monkeypox and 2) collect efficacy and safety information concerning such use. This explainer deals with both the US Centers for Disease Control and Prevention (CDC)-run Expanded Access program for TPOXX and the only trial of Tecovirimat as a treatment for monkeypox currently underway in the United States, the Study of Tecovirimat for Human Monkeypox Virus (STOMP). This explainer is up-to-date as of October 25, 2022. Read more
31Oct2022
Expanded Access for Tecovirimat (TPOXX): An Explainer for IRB and other regulatory professionals
Tags:
31 Oct
No comments